Qilu has another class of new drugs to attack the first oral dissolved membrane will be approved Qilu and another class of new drugs to attack the first oral soluble membrane will be approved

On January 9, Qilu Pharmaceutical's class 1 new drug injection QLS31901 clinical application was accepted by CDE contractor, acceptance number CXSL2100012.
injection QLS31901 is the first new class 1 drug to be declared clinically by Qilu Pharmaceuticals in 2021.
recent years, Qilu Pharmaceuticals in the field of innovative drugs, in 2020 a total of 4 new class 1 drugs submitted clinical applications, all therapeutic biological products.
2020 Qilu Pharmaceuticals declared clinical class 1 new drug Class 2 modified new drug Qilu Pharmaceutical has also begun to lay out, is about to enter the harvest period.
meters of intranet data show that Qilu Pharmaceuticals has 5 new class 2.2 drugs submitted for listing, respectively, Tadara non-oral dissolved membrane, O nitrogen flat mouth solution film, Mengluste sodium mouth solution membrane, hydrochloric acid methicillin oral dissolution membrane, alium oral dissolution membrane, are oral solution film.
, the registration status of the O nitrogen flat-mouth soluble film has been changed to "in the approval", is expected to be approved for listing recently, becoming the company's first oral soluble film agent.
Qilu Pharmaceuticals O nitrogen flat mouth dissolved membrane listing application Source: Mi net one-click search O nitrogen flat is mainly used for the treatment of schizophrenia, Minanet data show that in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal O nitrogen flat sales of more than 4 billion yuan.
At present, the domestic market of O nitrogen flat products have O nitrogen flat tablets, O nitrogen flat mouth collapse tablets and O nitrogen flat mouth dissolved membrane, O nitrogen flat mouth dissolved membrane only Howson Pharmaceuticals was approved, Qilu Pharmaceuticals is expected to become the second domestic.
source: Minet database, CDE